Drug intelligence / Profile preview

5-fluorouracil + cyclophosphamide + interferon alpha-2a + interleukin-2 + methotrexate

Development stage: Unknown
Lead developer: Takeda
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous, Intramuscular

Overview

A combination chemotherapy and immunotherapy regimen consisting of three chemotherapeutic agents (5-fluorouracil, cyclophosphamide, and methotrexate) and two immunotherapy agents (interferon alpha-2a and interleukin-2). The chemotherapy components work by different mechanisms: 5-fluorouracil stops cells from making and repairing DNA, cyclophosphamide stops cancer cells from reproducing, and methotrexate interferes with DNA synthesis. The immunotherapy components (interferon alpha-2a and interleukin-2) likely work by enhancing the immune response against cancer cells.

Targets

TS (Thymidylate synthase)IFNAR2 (Interferon alpha/beta receptor subunit 2)IL-2R (Interleukin-2/interleukin-15 receptor complex)IFNAR (Immune system modulation via type I interferon receptor)DHFR (Dihydrofolate reductase)DNA

Beyond the preview

Go deeper on 5-fluorouracil + cyclophosphamide + interferon alpha-2a + interleukin-2 + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-fluorouracil + cyclophosphamide + interferon alpha-2a + interleukin-2 + methotrexate.

Explore the full profile